Department of Pediatrics, CHU Nice, France.
Eur J Cancer. 2011 Jan;47(2):239-47. doi: 10.1016/j.ejca.2010.10.019. Epub 2010 Nov 20.
To evaluate the prognostic significance of the initial cerebro-spinal fluid (CSF) involvement of children with ALL enrolled from 1989 to 1996 in the EORTC 58881 trial.
Patients (2025) were categorised according to initial central nervous system (CNS) status: CNS-1 (CNS negative, n=1866), CNS-2 (<5 leucocytes/mm(3), CSF with blasts, n=50), CNS-3 (CNS positive, n=49), TLP+ (TLP with blasts, n=60). CNS-directed therapy consisted in intravenous (i.v.) methotrexate (5 g/sqm) in 4-10 courses, and intrathecal methotrexate injections (10-20), according to CNS status. Cranial irradiation was omitted in all patients.
In the CNS1, TLP+, CNS2 and CNS3 group the 8-year EFS rate (SE%) was 69.7% (1.1%), 68.8% (6.2%), 71.3% (6.5%) and 68.3% (6.2%), respectively. The 8-year incidence of isolated CNS relapse (SE%) was 3.4% (0.4%), 1.7% (1.7%), 6.1% (3.5%) and 9.4% (4.5%), respectively, whereas the 8-year isolated or combined CNS relapse incidence was 7.6% (0.6%), 3.5% (2.4%), 10.2% (4.4%) and 11.7% (5.0%), respectively. Patients with CSF blasts had a higher rate of initial bad risk features. Multivariate analysis indicated that presence of blasts in the CSF had no prognostic value: (i) for EFS and OS; (ii) for isolated and isolated or combined CNS relapse; WBC count<25 × 10(9)/L and Medac E-coli asparaginase treatment were each related to a lower CNS relapse risk.
The presence of initial CNS involvement has no prognostic significance in EORTC 58881. Intensification of CNS-directed chemotherapy, without CNS radiation, is an effective treatment of initial meningeal leukaemic involvement.
评估 1989 年至 1996 年期间入组 EORTC 58881 试验的 ALL 患儿初始脑脊液(CSF)受累的预后意义。
根据初始中枢神经系统(CNS)状态,将患者(2025 例)分为以下几类:CNS-1(CNS 阴性,n=1866)、CNS-2(白细胞<5/mm3,CSF 有白血病细胞,n=50)、CNS-3(CNS 阳性,n=49)、TLP+(有白血病细胞的 TLP,n=60)。CNS 定向治疗包括静脉(i.v.)甲氨蝶呤(5 g/sqm),根据 CNS 状态进行 4-10 个疗程,鞘内注射甲氨蝶呤(10-20)。所有患者均未接受颅脑照射。
在 CNS1、TLP+、CNS2 和 CNS3 组中,8 年 EFS 率(SE%)分别为 69.7%(1.1%)、68.8%(6.2%)、71.3%(6.5%)和 68.3%(6.2%)。8 年孤立性 CNS 复发发生率(SE%)分别为 3.4%(0.4%)、1.7%(1.7%)、6.1%(3.5%)和 9.4%(4.5%),而 8 年孤立或联合 CNS 复发发生率分别为 7.6%(0.6%)、3.5%(2.4%)、10.2%(4.4%)和 11.7%(5.0%)。CSF 中有白血病细胞的患者初始不良风险特征的发生率较高。多变量分析表明,CSF 中存在白血病细胞对 EFS 和 OS 无预后意义:(i)对 EFS 和 OS 无预后意义;(ii)对孤立性和孤立性或联合性 CNS 复发无预后意义;白细胞计数<25×109/L 和 Medac 大肠杆菌天冬酰胺酶治疗均与较低的 CNS 复发风险相关。
EORTC 58881 中初始 CNS 受累无预后意义。强化 CNS 定向化疗,不进行 CNS 放疗,是治疗初始脑膜白血病受累的有效方法。